CN112316012A - 一种舒润抑菌凝胶及其制备方法 - Google Patents
一种舒润抑菌凝胶及其制备方法 Download PDFInfo
- Publication number
- CN112316012A CN112316012A CN202011306655.3A CN202011306655A CN112316012A CN 112316012 A CN112316012 A CN 112316012A CN 202011306655 A CN202011306655 A CN 202011306655A CN 112316012 A CN112316012 A CN 112316012A
- Authority
- CN
- China
- Prior art keywords
- parts
- soothing
- ethanol
- gel
- bacteriostatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 230000003020 moisturizing effect Effects 0.000 title description 11
- 238000001879 gelation Methods 0.000 title description 2
- 230000003385 bacteriostatic effect Effects 0.000 claims abstract description 74
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 42
- 241000241413 Propolis Species 0.000 claims abstract description 33
- 229940069949 propolis Drugs 0.000 claims abstract description 33
- 239000000341 volatile oil Substances 0.000 claims abstract description 30
- 239000008213 purified water Substances 0.000 claims abstract description 27
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 23
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 21
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 21
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 21
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims abstract description 9
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 9
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims abstract description 9
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims abstract description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 claims abstract description 8
- 241000220317 Rosa Species 0.000 claims abstract description 8
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 8
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 8
- 229960002233 benzalkonium bromide Drugs 0.000 claims abstract description 8
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 claims abstract description 8
- 229960001631 carbomer Drugs 0.000 claims abstract description 8
- 229930014456 matrine Natural products 0.000 claims abstract description 8
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 8
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 87
- 244000307697 Agrimonia eupatoria Species 0.000 claims description 33
- 235000000125 common agrimony Nutrition 0.000 claims description 33
- 241001071917 Lithospermum Species 0.000 claims description 25
- 240000009022 Smilax rotundifolia Species 0.000 claims description 19
- 235000003205 Smilax rotundifolia Nutrition 0.000 claims description 19
- 238000003756 stirring Methods 0.000 claims description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 9
- 241000628997 Flos Species 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 230000001376 precipitating effect Effects 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 239000011159 matrix material Substances 0.000 claims description 7
- 238000004042 decolorization Methods 0.000 claims description 4
- 241000726221 Gemma Species 0.000 claims description 3
- 229960005150 glycerol Drugs 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims 4
- 239000000499 gel Substances 0.000 abstract description 84
- 230000000052 comparative effect Effects 0.000 description 13
- 230000002195 synergetic effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 241001404789 Smilax glabra Species 0.000 description 9
- 241000222122 Candida albicans Species 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- 241000191967 Staphylococcus aureus Species 0.000 description 8
- 229940095731 candida albicans Drugs 0.000 description 8
- 238000013329 compounding Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- NEZONWMXZKDMKF-UHFFFAOYSA-N C.I. Natural Red 20 Chemical compound C1=CC(O)=C2C(=O)C(C(O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-UHFFFAOYSA-N 0.000 description 2
- 240000004035 Lithospermum officinale Species 0.000 description 2
- 235000011030 Lithospermum officinale Nutrition 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 206010008323 cervicitis Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 201000003988 chronic cervicitis Diseases 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- -1 luteolin glycoside Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Insects & Arthropods (AREA)
- Gynecology & Obstetrics (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本申请涉及妇科抑菌凝胶领域,具体公开了一种舒润抑菌凝胶及其制备方法,所述舒润抑菌凝胶由包含以下重量份的原料制成:金银花95‑105份;蜂胶45‑55份;薄菏精油8‑12份;透明质酸钠8‑12份;玫瑰精油0.5‑1.5份;苦参碱2‑4份;苯扎溴铵0.5‑1.5份;甘油10‑15份;三乙醇胺13‑17份;卡波姆12‑16份;尼泊金乙酯2.5‑3.5份;纯化水补足至1000份。本申请具有提高凝胶的抑菌效果的优点。
Description
技术领域
本申请涉及妇科抑菌凝胶领域,更具体地说,它涉及一种舒润抑菌凝胶及其制备方法。
背景技术
妇科凝胶是一种妇科药品,为凝胶剂,用于各种妇科阴道炎、宫颈炎的治疗,包括:细菌性阴道炎、滴虫性阴道炎、混合性阴道炎、淋球菌感染、慢性宫颈炎。具有消炎、杀菌、止痒作用。对金黄色葡萄球菌、大肠杆菌、淋球菌、白色念珠球菌、真菌、酵母菌等病原体微生物的生长有明显抑制作用。
相关技术中一般采用一种具有抑菌成分的中药搭配润滑剂、表面活性剂、增稠剂、防腐剂和水共同制成凝胶。
针对上述中的相关技术,发明人认为凝胶的抑菌效果有待提升。
发明内容
为了提高凝胶的抑菌效果,本申请提供一种舒润抑菌凝胶及其制备方法。
第一方面,本申请提供一种舒润抑菌凝胶,采用如下的技术方案:
一种舒润抑菌凝胶,所述舒润抑菌凝胶由包含以下重量份的原料制成:
金银花95-105份;
蜂胶45-55份;
薄菏精油8-12份;
透明质酸钠8-12份;
玫瑰精油0.5-1.5份;
苦参碱2-4份;
苯扎溴铵0.5-1.5份;
甘油10-15份;
三乙醇胺13-17份;
卡波姆12-16份;
尼泊金乙酯2.5-3.5份;
纯化水补足至1000份。
通过采用上述技术方案,金银花含有绿原酸、木犀草素苷等药理活性成分,可以抑制细菌体内蛋白质合成,对溶血性链球菌、金黄葡萄球菌、大肠杆菌、白色念珠菌等多种致病菌等有较强的抑制力,另外还可增强免疫力、消炎。蜂胶有润肤生肌、消炎止痛的功效,还具有抗菌、消炎、止痒、抗氧化、增强免疫的作用,对大肠杆菌、金黄色葡萄球菌、白色念珠菌、绿脓杆菌等有抑制作用。薄荷精油对大肠杆菌、金黄葡萄球菌、白色念珠菌有明显的抗菌活性,还可以排除体内毒素,具有清凉及镇定的效果,能收缩微血管,对发痒、发炎和灼伤具有舒缓作用。本申请采用金银花、蜂胶和薄荷精油复配使用时,可以协同增效,显著提高抑菌率。
可选的,所述舒润抑菌凝胶的原料还包括15-20份的紫草。
通过采用上述技术方案,紫草具有抗菌、抗炎作用,对金黄色葡萄球菌、大肠杆菌、白色念珠菌有抑制作用。能加速上皮生长,局部应用可促进创伤愈合,紫草能够进一步提高抑菌凝胶的抑菌效果。
可选的,所述舒润抑菌凝胶的原料还包括8-10份的仙鹤草。
通过采用上述技术方案,仙鹤草具有抗菌、抗炎作用,对枯草杆菌、金黄色葡萄球菌、大肠杆菌、白色念珠菌、绿脓杆菌、福氏痢疾杆菌及伤寒杆菌等均有抑制作用,该作用与仙鹤草中含有能生成缩合型鞣酐的鞣质有关,仙鹤草能够进一步提高抑菌凝胶的抑菌效果。
可选的,所述舒润抑菌凝胶的原料还包括14-18份的土茯苓。
通过采用上述技术方案,土茯苓对金黄色葡萄球菌、白色葡萄球菌、绿脓杆菌、大肠杆菌、白色念珠菌、伤寒杆菌、甲型链球菌、乙型链球菌均有明显的抑菌作用,土茯苓能够进一步提高抑菌凝胶的抑菌效果。
可选的,所述舒润抑菌凝胶由包含以下重量份的原料制成:
金银花100份;
蜂胶50份;
薄菏精油10份;
透明质酸钠10份;
玫瑰精油1份;
苦参碱3份;
苯扎溴铵1份;
甘油12.6份;
三乙醇胺15份;
卡波姆15份;
尼泊金乙酯3份;
纯化水补足至1000份。
通过采用上述技术方案,原料的配比按照上述特定比例进行复配时,可以得到较好的抑菌效果。
第二方面,本申请提供一种舒润抑菌凝胶的制备方法,采用如下的技术方案:
一种舒润抑菌凝胶的制备方法,包括以下步骤:
(1)将尼泊金乙酯用乙醇溶解,得到第一溶液;
(2)取金银花、蜂胶加水煎煮多次,过滤,合并滤液,加热浓缩至60℃下相对密度为1.1-1.2的浸膏,加入乙醇使乙醇体积浓度达到75%,搅拌混匀,醇沉,静置至少24h,取上清液回收乙醇至无醇味,加入纯化水,再加入活性炭脱色,得到纯化浸膏;
(3)取卡波姆、苦参碱,加入纯化水浸泡至少24小时,至充分溶胀,得到凝胶基质;
(4)将第一溶液、纯化浸膏加入到凝胶基质中,再加入苯扎溴铵、透明质酸钠、甘油、玫瑰精油、薄荷精油搅拌均匀,补加纯化水至足量,滴入三乙醇胺调至pH至6-7,搅拌混匀,得到舒润抑菌凝胶。
通过采用上述技术方案,尼泊金乙酯用乙醇溶解后更容易分散,金银花、蜂胶一起进行提取得到第一溶液,将第一溶液、纯化浸膏加入到凝胶基质中后,再加入其它原料,可以促进水相成分和油相成分分散、混合均匀,三乙醇胺调节pH至6-7,降低了抑菌凝胶的刺激性。
可选的,所述步骤(2)具体包括:取金银花、蜂胶加水煎煮两次,第一次加7-8倍重量的纯化水,煎煮1-2小时;第二次加6-7倍重量的纯化水,煎煮1-2小时,过滤,合并两次滤液,加热浓缩至60℃下相对密度为1.1-1.2的浸膏,加入乙醇使乙醇体积浓度达到75%,搅拌混匀,醇沉,静置至少24h,取上清液回收乙醇至无醇味,加入纯化水,再加入活性炭脱色,得到纯化浸膏。
通过采用上述技术方案,两次煎煮可以充分提取金银花中的有效成分,醇沉可以除去杂质保留有效成分,活性炭脱色后可以使凝胶更加透明。
可选的,所述步骤(2)具体包括:取金银花、蜂胶、紫草、仙鹤草、土茯苓加水煎煮多次,过滤,合并滤液,加热浓缩至60℃下相对密度为1.1-1.2的浸膏,加入乙醇使乙醇体积浓度达到75%,搅拌混匀,醇沉,静置至少24h,取上清液回收乙醇至无醇味,加入纯化水,再加入活性炭脱色,得到纯化浸膏;其中,紫草、仙鹤草、土茯苓的重量份数分别为15-20份、8-10份、14-18份。
通过采用上述技术方案,采用金银花、蜂胶和薄荷精油复配使用时,可以协同增效,提高抑菌率;增加了紫草、仙鹤草和土茯苓后,紫草、仙鹤草和土茯苓复配使用,可以协同增效,进一步提升抑菌率。
综上所述,本申请具有以下有益效果:
1、由于本申请采用采用金银花、蜂胶和薄荷精油复配使用时,可以协同增效,显著提高抑菌率。
2、本申请中优选加入了紫草、仙鹤草和土茯苓,紫草、仙鹤草和土茯苓复配使用,可以协同增效,进一步提升抑菌率。
具体实施方式
以下结合实施例对本申请作进一步详细说明。
实施例
实施例1
一种舒润抑菌凝胶,原料的重量与配比如表1所示。舒润抑菌凝胶的制备方法,包括以下步骤:
(1)将尼泊金乙酯用乙醇溶解,得到第一溶液;
(2)取金银花、蜂胶加水煎煮两次,第一次加8倍重量的纯化水,煎煮1.5小时;第二次加6倍重量的纯化水,煎煮1小时,过滤,合并两次滤液,加热浓缩至60℃下相对密度为1.1-1.2的浸膏,加入乙醇使乙醇体积浓度达到75%,搅拌混匀,醇沉,静置24h,取上清液回收乙醇至无醇味,加入纯化水,再加入活性炭脱色,得到纯化浸膏;
(3)取卡波姆、苦参碱,加入纯化水浸泡24小时,至充分溶胀,得到凝胶基质;
(4)将第一溶液、纯化浸膏加入到凝胶基质中,再加入苯扎溴铵、透明质酸钠、甘油、玫瑰精油、薄荷精油搅拌均匀,补加纯化水至足量,滴入三乙醇胺调至pH至7,搅拌混匀,得到舒润抑菌凝胶。
实施例2-4
一种舒润抑菌凝胶,与实施例1的不同之处在于,原料及其相应的重量如表1所示。
表1实施例1-4中的原料及其重量(g)
实施例5
一种舒润抑菌凝胶,与实施例1的不同之处在于,原料还包括15g紫草,步骤(2)中紫草与金银花、蜂胶一起加水煎煮两次。
实施例6
一种舒润抑菌凝胶,与实施例5的不同之处在于,紫草的重量为18g。
实施例7
一种舒润抑菌凝胶,与实施例5的不同之处在于,紫草的重量为20g。
实施例8
一种舒润抑菌凝胶,与实施例5的不同之处在于,紫草的重量为10g。
实施例9
一种舒润抑菌凝胶,与实施例5的不同之处在于,紫草的重量为43g。
实施例10
一种舒润抑菌凝胶,与实施例1的不同之处在于,原料还包括8g仙鹤草,步骤(2)中仙鹤草与金银花、蜂胶一起加水煎煮两次。
实施例11
一种舒润抑菌凝胶,与实施例10的不同之处在于,仙鹤草的重量为9g。
实施例12
一种舒润抑菌凝胶,与实施例10的不同之处在于,仙鹤草的重量为10g。
实施例13
一种舒润抑菌凝胶,与实施例10的不同之处在于,仙鹤草的重量为5g。
实施例14
一种舒润抑菌凝胶,与实施例10的不同之处在于,仙鹤草的重量为43g。
实施例15
一种舒润抑菌凝胶,与实施例1的不同之处在于,原料还包括14g土茯苓,步骤(2)中土茯苓与金银花、蜂胶一起加水煎煮两次。
实施例16
一种舒润抑菌凝胶,与实施例15的不同之处在于,土茯苓的重量为16g。
实施例17
一种舒润抑菌凝胶,与实施例15的不同之处在于,土茯苓的重量为18g。
实施例18
一种舒润抑菌凝胶,与实施例15的不同之处在于,土茯苓的重量为10g。
实施例19
一种舒润抑菌凝胶,与实施例15的不同之处在于,土茯苓的重量为43g。
实施例20
一种舒润抑菌凝胶,与实施例1的不同之处在于,原料还包括18g紫草和25g仙鹤草,步骤(2)中紫草、仙鹤草与金银花、蜂胶一起加水煎煮两次。
实施例21
一种舒润抑菌凝胶,与实施例1的不同之处在于,原料还包括27g仙鹤草和16g土茯苓,步骤(2)中仙鹤草、土茯苓与金银花、蜂胶一起加水煎煮两次。
实施例22
一种舒润抑菌凝胶,与实施例1的不同之处在于,原料还包括18g紫草、9g仙鹤草和16g土茯苓,步骤(2)具体包括:取金银花、蜂胶、紫草、仙鹤草、土茯苓加水煎煮两次,第一次加8倍重量的纯化水,煎煮1.5小时;第二次加6倍重量的纯化水,煎煮1小时,过滤,合并两次滤液,加热浓缩至60℃下相对密度为1.1-1.2的浸膏,加入乙醇使乙醇体积浓度达到75%,搅拌混匀,醇沉,静置24h,取上清液回收乙醇至无醇味,加入纯化水,再加入活性炭脱色,得到纯化浸膏。
对比例
对比例1
一种舒润抑菌凝胶,与实施例1的不同之处在于,蜂胶和薄荷精油替换为等重量的金银花。
对比例2
一种舒润抑菌凝胶,与实施例1的不同之处在于,金银花和薄荷精油替换为等重量的蜂胶。
对比例3
一种舒润抑菌凝胶,与实施例1的不同之处在于,金银花和蜂胶替换为等重量的薄荷精油。
对比例4
一种舒润抑菌凝胶,与实施例1的不同之处在于,金银花的重量为60g。
对比例5
一种舒润抑菌凝胶,与实施例1的不同之处在于,蜂胶的重量为30g。
对比例6
一种舒润抑菌凝胶,与实施例1的不同之处在于,薄荷精油的重量为20g。
性能检测试验
试验方法:按照GB15979-2002《一次性使用卫生用品卫生标准》附录C4以及《消毒技术规范》2002版中的试验条件,测试实施例1-22和对比例1-6中的抑菌凝胶对大肠杆菌(8099)、白色念珠菌(ATCC10231)、金黄色葡萄球菌(ATCC6538)作用5min时的抑菌率,试验重复三次,取平均值,抑菌试验为载体试验,试验温度20℃±1℃。
实施例1-22中抑菌凝胶的微生物学指标和阴道粘膜刺激试验均符合《一次性使用卫生用品卫生标准》以及《消毒技术规范》2002版的相关要求。
表2抑菌率测试结果
结合实施例1-22和对比例1-6并结合表2可以看出,实施例1-3采用金银花、蜂胶和薄荷精油复配,对三种致病菌的抑菌率均在90%以上,说明本申请的抑菌凝胶具有较强抑菌作用。对比例1仅采用金银花时,抑菌率仅有60%左右,对比例2仅采用蜂胶时,抑菌率仅有61%左右,对比例3仅采用薄荷精油时,抑菌率仅有60%左右,说明金银花、蜂胶和薄荷精油单独使用时,抑菌效果较弱,但是实施例1将金银花、蜂胶和薄荷精油复配使用时,可以协同增效,显著提高抑菌率。
对比例4-6中,金银花、蜂胶和薄荷精油的用量不在本申请的范围内时,抑菌率有一定的下降,说明金银花、蜂胶和薄荷精油的用量会影响抑菌率。
实施例4改变了原料的配比后,抑菌率与实施例1相比提高了1%左右,说明原料的配比按照实施例4进行复配时,可以得到较好的抑菌效果。
实施例5-7在实施例1的基础上增加了紫草后,抑菌率明显提升,说明紫草能够进一步提高抑菌凝胶的抑菌效果,实施例8加入的紫草较少时,抑菌率提升较少,实施例9加入的紫草超过本申请的最高用量时,抑菌率没有明显提升,反而造成成本上升,说明紫草的用量在15-20份时能够较好的提高抑菌效果。
实施例10-12在实施例1的基础上增加了仙鹤草后,抑菌率明显提升,说明仙鹤草能够进一步提高抑菌凝胶的抑菌效果,实施例13加入的仙鹤草较少时,抑菌率提升较少,实施例14加入的仙鹤草超过本申请的最高用量时,抑菌率没有明显提升,反而造成成本上升,说明仙鹤草的用量在8-10份时能够较好的提高抑菌效果。
实施例15-17在实施例1的基础上增加了土茯苓后,抑菌率明显提升,说明土茯苓能够进一步提高抑菌凝胶的抑菌效果,实施例18加入的土茯苓较少时,抑菌率提升较少,实施例19加入的土茯苓超过本申请的最高用量时,抑菌率没有明显提升,反而造成成本上升,说明土茯苓的用量在14-18份时能够较好的提高抑菌效果。
实施例20在实施例1的基础上增加了紫草和仙鹤草后,抑菌率明显提高,但是没有发现有协同作用,说明紫草和仙鹤草复配,可以共同提高抑菌效果,但是没有协同作用;实施例21在实施例1的基础上增加了仙鹤草和土茯苓后,抑菌率明显提高,但是没有发现有协同作用,说明仙鹤草和土茯苓复配,可以共同提高抑菌效果,但是没有协同作用;实施例22在实施例1的基础上增加了紫草、仙鹤草和土茯苓后,发现抑菌率明显提高,而且具有协同增效的作用,说明紫草、仙鹤草和土茯苓复配使用时,可以协同增效,显著提升抑菌率。
本具体实施例仅仅是对本申请的解释,其并不是对本申请的限制,本领域技术人员在阅读完本说明书后可以根据需要对本实施例做出没有创造性贡献的修改,但只要在本申请的权利要求范围内都受到专利法的保护。
Claims (8)
1.一种舒润抑菌凝胶,其特征在于,所述舒润抑菌凝胶由包含以下重量份的原料制成:
金银花95-105份;
蜂胶45-55份;
薄菏精油8-12份;
透明质酸钠8-12份;
玫瑰精油0.5-1.5份;
苦参碱2-4份;
苯扎溴铵0.5-1.5份;
甘油10-15份;
三乙醇胺13-17份;
卡波姆12-16份;
尼泊金乙酯2.5-3.5份;
纯化水补足至1000份。
2.根据权利要求1所述的一种舒润抑菌凝胶,其特征在于:所述舒润抑菌凝胶的原料还包括15-20份的紫草。
3.根据权利要求1所述的一种舒润抑菌凝胶,其特征在于:所述舒润抑菌凝胶的原料还包括8-10份的仙鹤草。
4.根据权利要求1所述的一种舒润抑菌凝胶,其特征在于:所述舒润抑菌凝胶的原料还包括14-18份的土茯苓。
5.根据权利要求1所述的一种舒润抑菌凝胶,其特征在于:所述舒润抑菌凝胶由包含以下重量份的原料制成:
金银花100份;
蜂胶50份;
薄菏精油10份;
透明质酸钠10份;
玫瑰精油1份;
苦参碱3份;
苯扎溴铵1份;
甘油12.6份;
三乙醇胺15份;
卡波姆15份;
尼泊金乙酯3份;
纯化水补足至1000份。
6.权利要求1-5中任一项所述的一种舒润抑菌凝胶的制备方法,其特征在于:包括以下步骤:
(1)将尼泊金乙酯用乙醇溶解,得到第一溶液;
(2)取金银花、蜂胶加水煎煮多次,过滤,合并滤液,加热浓缩至60℃下相对密度为1.1-1.2的浸膏,加入乙醇使乙醇体积浓度达到75%,搅拌混匀,醇沉,静置至少24h,取上清液回收乙醇至无醇味,加入纯化水,再加入活性炭脱色,得到纯化浸膏;
(3)取卡波姆、苦参碱,加入纯化水浸泡至少24小时,至充分溶胀,得到凝胶基质;
(4)将第一溶液、纯化浸膏加入到凝胶基质中,再加入苯扎溴铵、透明质酸钠、甘油、玫瑰精油、薄荷精油搅拌均匀,补加纯化水至足量,滴入三乙醇胺调至pH至6-7,搅拌混匀,得到舒润抑菌凝胶。
7.根据权利要求6所述的一种舒润抑菌凝胶的制备方法,其特征在于:所述步骤(2)具体包括:取金银花、蜂胶加水煎煮两次,第一次加7-8倍重量的纯化水,煎煮1-2小时;第二次加6-7倍重量的纯化水,煎煮1-2小时,过滤,合并两次滤液,加热浓缩至60℃下相对密度为1.1-1.2的浸膏,加入乙醇使乙醇体积浓度达到75%,搅拌混匀,醇沉,静置至少24h,取上清液回收乙醇至无醇味,加入纯化水,再加入活性炭脱色,得到纯化浸膏。
8.根据权利要求6所述的一种舒润抑菌凝胶的制备方法,其特征在于:所述步骤(2)具体包括:取金银花、蜂胶、紫草、仙鹤草、土茯苓加水煎煮多次,过滤,合并滤液,加热浓缩至60℃下相对密度为1.1-1.2的浸膏,加入乙醇使乙醇体积浓度达到75%,搅拌混匀,醇沉,静置至少24h,取上清液回收乙醇至无醇味,加入纯化水,再加入活性炭脱色,得到纯化浸膏;其中,紫草、仙鹤草、土茯苓的重量份数分别为15-20份、8-10份、14-18份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011306655.3A CN112316012A (zh) | 2020-11-19 | 2020-11-19 | 一种舒润抑菌凝胶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011306655.3A CN112316012A (zh) | 2020-11-19 | 2020-11-19 | 一种舒润抑菌凝胶及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112316012A true CN112316012A (zh) | 2021-02-05 |
Family
ID=74321798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011306655.3A Pending CN112316012A (zh) | 2020-11-19 | 2020-11-19 | 一种舒润抑菌凝胶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112316012A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115554346A (zh) * | 2022-08-31 | 2023-01-03 | 上海市第五人民医院 | 一种用于泌尿生殖系统的中药组合物 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1628771A (zh) * | 2004-08-26 | 2005-06-22 | 唐秋海 | 治疗妇科疾病的洗剂及其制备方法 |
CN102657245A (zh) * | 2012-04-19 | 2012-09-12 | 沃德国泰(北京)科技发展有限公司 | 一种采用植物提取物制成的消毒液及其制备方法 |
CN104042672A (zh) * | 2014-05-30 | 2014-09-17 | 西安交通大学 | 一种中药复方阴道冲洗液及其制备方法和应用 |
CN108096396A (zh) * | 2018-03-07 | 2018-06-01 | 西安璀璨生物科技有限责任公司 | 一种用于阴道黏膜抑菌的中药凝胶组合物 |
CN108245602A (zh) * | 2018-04-18 | 2018-07-06 | 张国壮 | 一种治疗皮肤病的外用中药组合物 |
CN109288910A (zh) * | 2018-10-19 | 2019-02-01 | 湖北华信制药有限公司 | 一种治疗妇科阴道炎的中药清洗液及其制备方法 |
CN110179877A (zh) * | 2019-04-09 | 2019-08-30 | 长沙康威日用品有限公司 | 草本抑菌乳膏 |
-
2020
- 2020-11-19 CN CN202011306655.3A patent/CN112316012A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1628771A (zh) * | 2004-08-26 | 2005-06-22 | 唐秋海 | 治疗妇科疾病的洗剂及其制备方法 |
CN102657245A (zh) * | 2012-04-19 | 2012-09-12 | 沃德国泰(北京)科技发展有限公司 | 一种采用植物提取物制成的消毒液及其制备方法 |
CN104042672A (zh) * | 2014-05-30 | 2014-09-17 | 西安交通大学 | 一种中药复方阴道冲洗液及其制备方法和应用 |
CN108096396A (zh) * | 2018-03-07 | 2018-06-01 | 西安璀璨生物科技有限责任公司 | 一种用于阴道黏膜抑菌的中药凝胶组合物 |
CN108245602A (zh) * | 2018-04-18 | 2018-07-06 | 张国壮 | 一种治疗皮肤病的外用中药组合物 |
CN109288910A (zh) * | 2018-10-19 | 2019-02-01 | 湖北华信制药有限公司 | 一种治疗妇科阴道炎的中药清洗液及其制备方法 |
CN110179877A (zh) * | 2019-04-09 | 2019-08-30 | 长沙康威日用品有限公司 | 草本抑菌乳膏 |
Non-Patent Citations (5)
Title |
---|
侯丽敏: "初探中药治疗老年性阴道炎", 《中国民族民间医药》 * |
唐壹蓉: "自拟一洗灵治疗外阴及阴道炎疗效观察", 《现代中西医结合杂志》 * |
李玉杰,等: "玫瑰精油的化学成分及其抗菌活性", 《植物研究》 * |
蔡永敏,等主编: "《最新中药药理与临床应用》", 31 January 1999, 华夏出版社 * |
陕西康乐实业有限公司: "Q/SXKL 0302-2020 触秘®舒润抑菌凝胶", 《企业标准信息公共服务平台》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115554346A (zh) * | 2022-08-31 | 2023-01-03 | 上海市第五人民医院 | 一种用于泌尿生殖系统的中药组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106334067B (zh) | 含银离子抗菌剂的妇科凝胶、制备方法及应用 | |
CN109078165B (zh) | 一种用于女性私处护理的组合物及其制备方法与应用 | |
CN111202822A (zh) | 一种妇科外用抗菌喷剂及其制备方法 | |
EP2575971B1 (en) | Combined plant extracts for use in the treatment of microbial infections | |
CN113081928B (zh) | 一种植物抑菌凝胶及其制备方法和应用 | |
CN107412585B (zh) | 一种绿色环保型免洗手消毒凝胶及其制备方法 | |
CN107961399A (zh) | 一种含复合抗菌剂的水性人体润滑液 | |
US10478463B2 (en) | External-use medicament for cleaning and care of the ovaries, vagina, and vulva | |
WO2020019929A1 (zh) | 复方中药抗菌组合物及其在洗护产品中的应用 | |
CN112237559A (zh) | 一种消毒组合物及其制备方法 | |
CN112915055A (zh) | 一种舒缓多效除螨组合物及其应用 | |
CN111184675A (zh) | 一种免洗消毒组合物及其制备方法与免洗消毒啫喱 | |
CN111973515A (zh) | 一种抑菌修复植物提取组合物、其制备方法及应用 | |
CN105267106A (zh) | 一种蒲公英中药洗手液及其制备方法 | |
CN112316012A (zh) | 一种舒润抑菌凝胶及其制备方法 | |
CN108186738B (zh) | 一种含美洲大蠊提取物的妇科凝胶剂及其制备方法 | |
Nayak et al. | An in vitro study to determine the effect of Terminalia chebula extract and its formulation on Streptococcus mutans | |
CN108379349B (zh) | 抗菌消炎口腔冲洗液及其制备方法和应用 | |
CN107913234B (zh) | 一种鹿茸草牙膏及其制备方法 | |
CN105535723A (zh) | 一种治疗外阴炎的中药组合物及其外用制剂 | |
CN114432382A (zh) | 一种女性私密护理凝胶及其制备方法与应用 | |
Dhurve et al. | Formulations of Panchavalkala As Vrana Shodhana and Vrana Ropana: A Brief Review | |
CN108785212B (zh) | 一种具有抑菌和抗螨的中药复合物及其应用 | |
CN111012703A (zh) | 一种纯天然pH平衡护理液及其制备方法 | |
CN113967184B (zh) | 一种抗菌消炎的复方黄柏组合物及其制备方法与含有该组合物的化妆品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210205 |